Dr Neunert
Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2010;2010(1):377-84. Abstract
Kuter DJ et al. Cognitive impairment among patients with chronic immune thrombocytopenia. Br J Haematol 2024;205(1):291-9. Abstract
Leaf R et al. Immune thrombocytopenia in patients treated with immune checkpoint inhibitors. ASH 2025;Abstract 841.
Mithoowani S et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: A systematic review and meta-analysis. Lancet Haematol 2016;3(10):e489-96. Abstract
Moulis G et al. Epidemiology of incident immune thrombocytopenia: A nationwide population-based study in France. Blood 2014;124(22):3308-15. Abstract
Neunert C et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019;3(23):3829-66. Abstract
Prof Zaja
Boccia R et al. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol 2020;190(6):933-8. Abstract
Bussel J et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 2018;93(7):921-30. Abstract
Cheng G et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet 2011;377(9763):393-402. Abstract
Cooper N et al. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Ther Adv Hematol 2021;12. Abstract
Ghanima W et al. The prolong trial: A two phase randomized placebo-controlled trial to optimize rituximab response with dexamethasone and maintenance therapy with low dose rituximab in immune thrombocytopenia (ITP) patients. ASH 2025;Abstract 736.
Mingot ME et al. A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study. ASH 2025;Abstract 733.
Provan D et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3(22):3780-817. Abstract
Zaja F et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. Blood Rev 2020;41. Abstract
Dr Al-Samkari
Al-Samkari H et al. Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment. ASH 2025;Abstract LBA-2.
Broome CM et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): A multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2023;402(10413):1648-59. Abstract
Choi P et al. Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy. ASH 2025;Abstract 844.
Cooper N et al. Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP). ASH 2025;Abstract 1254.
Cuker A et al. Ianalumab plus eltrombopag in immune thrombocytopenia. N Engl J Med 2025;[Online ahead of print]. Abstract
Jiang D et al. Changing paradigms in ITP management: Newer tools for an old disease. Transfus Med Rev 2022;36(4):188-94. Abstract
Kuter D et al. Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent/chronic immune thrombocytopenia in the long-term extension period of the phase 3 LUNA3 study. ASH 2025;Abstract 1260.
Kuter DJ et al. Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: The phase 3 LUNA3 study. Blood 2025;145(24):2914-26. Abstract
Kuter DJ et al. Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study. International Society of Thrombosis and Haemostasis 2024;Abstract LB 01.01.
Kuter DJ et al. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Rev 2021;49. Abstract
Kuter DJ et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: A subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol 2019;185(3):503-13. Abstract